Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Authors:
Open Access
- 1 June 2012
- journal article
- review article
- Published by Taylor & Francis in Core Evidence
- Vol. 7, 21-8
Abstract
Peer reviewed article authored by (Chao EC). Read article or submit your manuscript for publishing.Keywords
This publication has 31 references indexed in Scilit:
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine, 2010
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic RatsDiabetes, 2008
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- Islet cell failure in type 2 diabetesJournal of Clinical Investigation, 2006
- The sodium/glucose cotransport family SLC5Pflügers Archiv - European Journal of Physiology, 2004
- Molecular Analysis of the SGLT2 Gene in Patients with Renal GlucosuriaJournal of the American Society of Nephrology, 2003
- Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteinsBritish Journal of Nutrition, 2003
- Oral Antihyperglycemic Therapy for Type 2 DiabetesJAMA, 2002
- Renal Na+-glucose cotransportersAmerican Journal of Physiology-Renal Physiology, 2001
- Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.Journal of Clinical Investigation, 1987